Rob Wood
Episode 217
Geordie lad done good in pharma
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rob Wood, pharma portfolio investor and Founder.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob, covering:
- Identifying a niche in the pharma services space that led to working with top 50 Big Pharma
- Growing STEM into an international powerhouse before eventually selling to UDG Healthcare
- Life as a pharma portfolio advisor and investor of seven pharma services companies
- Creating an academy that will introduce entrepreneurship to hundreds of thousands of kids
- How AI will impact the commercialization of new and existing drugs
Rob Wood is an experienced entrepreneur in the pharma services industry. He founded, scaled, and sold STEM for €120 million, expanding into 51 countries and working with all of the top 50 pharmaceutical companies. STEM grew to over 1,000 staff globally and received the Queen’s Award for International Trade.
After selling STEM, Rob joined UDG plc as CEO & President of Advisory and Head of Group Business Development, leading multiple healthcare consultancies and re-modelling business development across 28 companies.
Today, Rob serves as Chairman or Non-Executive Director for several healthcare service companies, focusing on growth, leadership, and investment opportunities. He holds an MBA from Newcastle University.
He recently founded the Rob Wood Enterprising Futures Academy in conjunction with Newcastle University.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
